Tue 9/19/2017 12:57 ET
DJIA22380.5049.150.22%SOLAR22.490.220.99%GOLD1309.401.440.11%Shanghai3136.7734.501.10%
S&P 5002507.463.510.14%BANKS25.270.210.84%OIL49.490.420.84%Nikkei20299.38397.871.96%
NASDAQ6461.536.900.11%SEMI92.730.370.40%US/EU1.200.000.17%Futures2505.002.250.09%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Stocks For A Different Jungle    If it belongs at the Pit it doesn't belong here.

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  
From: madrid (Rep: 0)Date: 07/27/2017 15:31
Forum: Stocks For A Different Jungle - Msg #19115Thread #673941992 (Rec: 0)
AB Biotics


AB-Biotics press release
New publication on AB-Kolicare®
Barcelona, Spain, April 5th 2017 – AB-Biotics is pleased to announce the publication of a new and promising clinical evidence on its probiotic formula AB-Kolicare, containing its proprietary strains Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330, in the management of excessive crying in infant colic.

The study, entitled “Probiotic treatment with AB-Kolicare® causes changes in the microbiota which correlate with a reduction in excessive crying” was recently published in the International Journal of Pharma and Bio Sciences. The research was performed on colicky infants from a single center in Spain and concluded that treatment with AB-Kolicare® is able to trigger changes in the microbiota of infant colic which correlate with a reduction in excessive crying. In addition, the changes validate the capacity of the strains to antagonize the growth of opportunistic pathogenic bacteria, as a reduction in the pathogens of study is seen after treatment with AB-Kolicare. Finally, AB-Kolicare® help increase the abundance of particular populations described as protective against infant colic, such as Actinobacteria, and in particular, Bifidobacterium.

“This study has allowed us to confirm that the antagonism against enteropathogens over-represented in infant colic that we had previously observed in vitro are actually taking place in vivo” says Dr. Maria Tintoré, author of the study and Scientific Manager at AB-Biotics.

Dr. Jordi Cuñé, Chief Research Officer at AB-Biotics, also signing the publication, continues: “Gut microbiota represents a complex ecosystem that, when altered, can be involved in complications for health. Being able to modulate microbiota and restore it towards a healthy equilibrium is of great relevance for the development of new probiotic treatments. We are excited to see that with AB-Kolicare® supplementation we can increase bacterial diversity in only two weeks, and that this increase in diversity is translated clinically into a reduction in crying time.”

To obtain a copy of our latest publication or to learn more about the scientific research conducted with AB-Kolicare®, please contact us at munoz@ab-biotics.com.

https://www.probiotaamericas.com/ab-biotics-pr/

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser madrid: Reward | Watch | Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.